The utility of ?-site amyloid-? precursor protein (A?PP) cleaving enzyme 1 (BACE1) activity and soluble A?PP ? (sA?PP?) levels in cerebrospinal fluid (CSF) in detecting Alzheimer's disease (AD) is still elusive.BACE1 activity and sA?PP? concentration were measured in patients with AD dementia (n = 56) and mild cognitive impairment (MCI) due to AD (n = 76) with abnormal routine AD CSF markers, in patients with MCI with normal CSF markers (n = 39), and in controls without preclinical AD (n = 48). In a subsample with available 18F-fluorodeoxyglucose positron emission tomography (FDG PET) data, ordinal regression models were employed to compare the contribution of BACE1 and sA?PP? to correct diagnostic classification to that of FDG PET.BACE1 activity was significantly higher in patients with MCI due to AD compared to both controls and patients with MCI with normal CSF markers. sA?PP? did not differ between any of the studied groups. Interestingly, BACE1 activity was not found to be inferior to FDG PET as predictive covariate in differentiating between the diagnostic groups.Further studies using biomarker-underpinned diagnoses are warranted to shed more light on the potential diagnostic utility of BACE1 activity as AD biomarker candidate in MCI.     «

The utility of ?-site amyloid-? precursor protein (A?PP) cleaving enzyme 1 (BACE1) activity and soluble A?PP ? (sA?PP?) levels in cerebrospinal fluid (CSF) in detecting Alzheimer's disease (AD) is still elusive.BACE1 activity and sA?PP? concentration were measured in patients with AD dementia (n = 56) and mild cognitive impairment (MCI) due to AD (n = 76) with abnormal routine AD CSF markers, in patients with MCI with normal CSF markers (n = 39), and in controls without preclinical AD (n = 48)....     »